Long-term hepatitis B immune globulin (HBIG) has been shown to reduce hepatitis B virus (HBV) reinfection in patients transplanted for hepatitis B. Infection with hepatitis B may lead to hepatocellular carcinoma, a type of liver cancer. Therefore, the hepatitis-B vaccines are cancer-preventing vaccines. According to the Centers for Disease Control and Prevention (CDC), the hepatitis B vaccine was the first anti-cancer vaccine.
HBIG is prepared from the plasma of donors who have high antibody levels of the hepatitis B surface antigen. It is extracted from the Cohn fraction II. During the process, viruses are deactivated, and in the final steps, solvents used in the preparation are removed. The preparation is tested for absence of HIV, HCV, herpes virus, and reovirus.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Diethylstilbestrol | Diethylstilbestrol may increase the thrombogenic activities of Hepatitis B immune globulin. |
| Chlorotrianisene | Chlorotrianisene may increase the thrombogenic activities of Hepatitis B immune globulin. |
| Conjugated estrogens | Conjugated estrogens may increase the thrombogenic activities of Hepatitis B immune globulin. |
| Estrone | Estrone may increase the thrombogenic activities of Hepatitis B immune globulin. |
| Estradiol | Estradiol may increase the thrombogenic activities of Hepatitis B immune globulin. |
| Dienestrol | Dienestrol may increase the thrombogenic activities of Hepatitis B immune globulin. |
| Ethinylestradiol | Ethinylestradiol may increase the thrombogenic activities of Hepatitis B immune globulin. |
| Mestranol | Mestranol may increase the thrombogenic activities of Hepatitis B immune globulin. |
| Estriol | Estriol may increase the thrombogenic activities of Hepatitis B immune globulin. |
| Estrone sulfate | Estrone sulfate may increase the thrombogenic activities of Hepatitis B immune globulin. |
| Quinestrol | Quinestrol may increase the thrombogenic activities of Hepatitis B immune globulin. |
| Hexestrol | Hexestrol may increase the thrombogenic activities of Hepatitis B immune globulin. |
| Tibolone | Tibolone may increase the thrombogenic activities of Hepatitis B immune globulin. |
| Synthetic Conjugated Estrogens, A | Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Hepatitis B immune globulin. |
| Synthetic Conjugated Estrogens, B | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Hepatitis B immune globulin. |
| Polyestradiol phosphate | Polyestradiol phosphate may increase the thrombogenic activities of Hepatitis B immune globulin. |
| Esterified estrogens | Esterified estrogens may increase the thrombogenic activities of Hepatitis B immune globulin. |
| Zeranol | Zeranol may increase the thrombogenic activities of Hepatitis B immune globulin. |
| Equol | Equol may increase the thrombogenic activities of Hepatitis B immune globulin. |
| Promestriene | Promestriene may increase the thrombogenic activities of Hepatitis B immune globulin. |
| Methallenestril | Methallenestril may increase the thrombogenic activities of Hepatitis B immune globulin. |
| Epimestrol | Epimestrol may increase the thrombogenic activities of Hepatitis B immune globulin. |
| Moxestrol | Moxestrol may increase the thrombogenic activities of Hepatitis B immune globulin. |
| Estradiol acetate | Estradiol acetate may increase the thrombogenic activities of Hepatitis B immune globulin. |
| Estradiol benzoate | Estradiol benzoate may increase the thrombogenic activities of Hepatitis B immune globulin. |
| Estradiol cypionate | Estradiol cypionate may increase the thrombogenic activities of Hepatitis B immune globulin. |
| Estradiol valerate | Estradiol valerate may increase the thrombogenic activities of Hepatitis B immune globulin. |
| Biochanin A | Biochanin A may increase the thrombogenic activities of Hepatitis B immune globulin. |
| Formononetin | Formononetin may increase the thrombogenic activities of Hepatitis B immune globulin. |
| Estetrol | Estetrol may increase the thrombogenic activities of Hepatitis B immune globulin. |
| Cetuximab | The risk or severity of adverse effects can be increased when Cetuximab is combined with Hepatitis B immune globulin. |
| Human immunoglobulin G | The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Hepatitis B immune globulin. |
| Omalizumab | The risk or severity of adverse effects can be increased when Omalizumab is combined with Hepatitis B immune globulin. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with Hepatitis B immune globulin. |
| Abciximab | The risk or severity of adverse effects can be increased when Abciximab is combined with Hepatitis B immune globulin. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Hepatitis B immune globulin. |
| Indium In-111 satumomab pendetide | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Hepatitis B immune globulin. |
| Infliximab | The risk or severity of adverse effects can be increased when Infliximab is combined with Hepatitis B immune globulin. |
| Trastuzumab | The risk or severity of adverse effects can be increased when Trastuzumab is combined with Hepatitis B immune globulin. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Hepatitis B immune globulin. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Hepatitis B immune globulin. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Hepatitis B immune globulin. |
| Digoxin Immune Fab (Ovine) | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Hepatitis B immune globulin. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Hepatitis B immune globulin. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Hepatitis B immune globulin. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Hepatitis B immune globulin. |
| Capromab pendetide | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Hepatitis B immune globulin. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Hepatitis B immune globulin. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Hepatitis B immune globulin. |
| Natalizumab | The risk or severity of adverse effects can be increased when Natalizumab is combined with Hepatitis B immune globulin. |
| Palivizumab | The risk or severity of adverse effects can be increased when Palivizumab is combined with Hepatitis B immune globulin. |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with Hepatitis B immune globulin. |
| Bevacizumab | The risk or severity of adverse effects can be increased when Bevacizumab is combined with Hepatitis B immune globulin. |
| Technetium Tc-99m arcitumomab | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Hepatitis B immune globulin. |
| Eculizumab | The risk or severity of adverse effects can be increased when Eculizumab is combined with Hepatitis B immune globulin. |
| Panitumumab | The risk or severity of adverse effects can be increased when Panitumumab is combined with Hepatitis B immune globulin. |
| Ranibizumab | The risk or severity of adverse effects can be increased when Ranibizumab is combined with Hepatitis B immune globulin. |
| Galiximab | The risk or severity of adverse effects can be increased when Galiximab is combined with Hepatitis B immune globulin. |
| Pexelizumab | The risk or severity of adverse effects can be increased when Pexelizumab is combined with Hepatitis B immune globulin. |
| Afelimomab | The risk or severity of adverse effects can be increased when Afelimomab is combined with Hepatitis B immune globulin. |
| Epratuzumab | The risk or severity of adverse effects can be increased when Epratuzumab is combined with Hepatitis B immune globulin. |
| Bectumomab | The risk or severity of adverse effects can be increased when Bectumomab is combined with Hepatitis B immune globulin. |
| Oregovomab | The risk or severity of adverse effects can be increased when Oregovomab is combined with Hepatitis B immune globulin. |
| IGN311 | The risk or severity of adverse effects can be increased when IGN311 is combined with Hepatitis B immune globulin. |
| Adecatumumab | The risk or severity of adverse effects can be increased when Adecatumumab is combined with Hepatitis B immune globulin. |
| Labetuzumab | The risk or severity of adverse effects can be increased when Labetuzumab is combined with Hepatitis B immune globulin. |
| Matuzumab | The risk or severity of adverse effects can be increased when Matuzumab is combined with Hepatitis B immune globulin. |
| Fontolizumab | The risk or severity of adverse effects can be increased when Fontolizumab is combined with Hepatitis B immune globulin. |
| Bavituximab | The risk or severity of adverse effects can be increased when Bavituximab is combined with Hepatitis B immune globulin. |
| CR002 | The risk or severity of adverse effects can be increased when CR002 is combined with Hepatitis B immune globulin. |
| Rozrolimupab | The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Hepatitis B immune globulin. |
| Girentuximab | The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Girentuximab. |
| Obiltoxaximab | The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Obiltoxaximab. |
| XTL-001 | The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with XTL-001. |
| NAV 1800 | The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with NAV 1800. |
| Briakinumab | The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Briakinumab. |
| Otelixizumab | The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Otelixizumab. |
| AMG 108 | The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with AMG 108. |
| Iratumumab | The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Iratumumab. |
| Enokizumab | The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Enokizumab. |
| Ramucirumab | The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Ramucirumab. |
| Farletuzumab | The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Farletuzumab. |
| Veltuzumab | The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Veltuzumab. |
| Ustekinumab | The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Ustekinumab. |
| Trastuzumab emtansine | The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Trastuzumab emtansine. |
| PRO-542 | The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with PRO-542. |
| TNX-901 | The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with TNX-901. |
| Inotuzumab ozogamicin | The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Inotuzumab ozogamicin. |
| RI 624 | The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with RI 624. |
| Stamulumab | The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with MYO-029. |
| CT-011 | The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with CT-011. |
| Leronlimab | The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Leronlimab. |
| Glembatumumab vedotin | The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Glembatumumab vedotin. |
| Olaratumab | The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Olaratumab. |
| IPH 2101 | The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with IPH 2101. |
| TB-402 | The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with TB-402. |
| Caplacizumab | The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Caplacizumab. |
| IMC-1C11 | The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with IMC-1C11. |
| Eldelumab | The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Eldelumab. |
| Lumiliximab | The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Lumiliximab. |